UnknownNot Applicable

Prevalence of Liver Fibrosis and Progression of Liver Fibrosis

Switzerland195 participantsStarted 2010-10

Plain-language summary

Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first to evaluate the prevalence of liver fibrosis and cirrhosis in HIV-infected patients with chronic ALT elevation and no chronic viral hepatitis using non-invasive diagnostic tests and second to find associated factors with significant fibrosis and cirrhosis. In a second longitudinal part we intend to assess fibrosis progression within 1 and 3 years.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: Case patients: * HIV-1 infection * no hepatitis B and C coinfection * chronic alanine aminotransferase (ALT) elevation after 1.1.2007 * signed informed consent * no other common cause of liver disease Control patients: * HIV-infection * no hepatitis B and C coinfection * no ALT elevation after 1.1.2002, the date when ALT values were regularly collected in the Swiss HIV Cohort Study (SHCS) * no known chronic liver disease Exclusion criteria: please see inclusion criteria

What they're measuring

Liverfibrosis

Timeframe: 3 years

Trial details

NCT IDNCT01208376

SponsorHelen Kovari-Kramer

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-08

View on ClinicalTrials.gov More HIV Infection and Chronic Alanine Aminotransferase Elevation trials